{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:40:03Z","timestamp":1790890803363,"version":"4.1.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T00:00:00Z","timestamp":1712275200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009018","name":"Shanghai Municipal Human Resources and Social Security Bureau","doi-asserted-by":"publisher","award":["EK00000861"],"award-info":[{"award-number":["EK00000861"]}],"id":[{"id":"10.13039\/501100009018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>Levofloxacin is widely used because of its broad-spectrum antimicrobial activity and convenient dosing schedule. However, the relevance of its use in children remains to be investigated. The purpose of this study is to investigate the efficacy and safety of levofloxacin use in children with severe infections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We conducted a retrospective observational study of patients &amp;lt;18 years of age who received levofloxacin intravenously in the Pediatric Intensive Care Unit (PICU) of our hospital during the period between 2021 and 2022. Patient demographics, course characteristics, clinical effectiveness, and adverse event correlations were extracted through a retrospective tabular review.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We included 25 patients treated with 28 courses of levofloxacin. The mean age of these children treated with levofloxacin was 4.41 years. Conversion of pathogenic microbiological test results to negative after levofloxacin treatment was detected in 11 courses (39.29%). A decrease in inflammatory markers, white blood cell or C-reactive protein counts, was detected in 18 courses (64.29%). A total of 57 adverse events occurred during the treatment period, of which 21 were possibly related to levofloxacin and no adverse events were probably related to levofloxacin.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The effectiveness of levofloxacin use in children with serious infections is promising, especially for the treatment of multidrug-resistant bacteria. Adverse events occurring during the initiation of levofloxacin therapy in children are reported to be relatively common, but in this study, only a small percentage of them were possibly related to levofloxacin, and none of them were highly possibly related to levofloxacin.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2024.1381742","type":"journal-article","created":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T04:39:33Z","timestamp":1712291973000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["A retrospective study of the efficacy and safety of levofloxacin in children with severe infection"],"prefix":"10.3389","volume":"12","author":[{"given":"Zhang","family":"Junqi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cai","family":"Jie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Jinglin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Jinmiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Guoping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhiping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1086\/655159","article-title":"Catheter-associated urinary tract infection IDSA guidelines: why the levofloxacin?","volume":"51","author":"Bush","year":"2010","journal-title":"Clin Infect Dis"},{"key":"B2","first-page":"7","article-title":"Guidelines for treatment of pneumonia in intensive care units","author":"Emmi","year":"2005","journal-title":"Infez Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1007\/s00120-017-0389-1","article-title":"Epidemiology, diagnostics, therapy, prevention and management of uncomplicated bacterial outpatient acquired urinary tract infections in adult patients: update 2017 of the interdisciplinary AWMF S3 guideline","volume":"56","author":"Kranz","year":"2017","journal-title":"Urologe"},{"key":"B4","doi-asserted-by":"publisher","first-page":"281","DOI":"10.23736\/S0026-4806.20.06810-X","article-title":"Treatment of Helicobacter pylori infection: a clinical practice update","volume":"112","author":"Zagari","year":"2021","journal-title":"Minerva Med"},{"key":"B5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1093\/cid\/ciz1082","article-title":"Guideline for antibacterial prophylaxis administration in pediatric cancer and hematopoietic stem cell transplantation","volume":"71","author":"Lehrnbecher","year":"2020","journal-title":"Clin Infect Dis"},{"key":"B6","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1016\/j.ijid.2022.07.029","article-title":"Pharmacokinetics and safety of WHO-recommended dosage and higher dosage of levofloxacin for tuberculosis treatment in children: a pilot study","volume":"122","author":"Jantarabenjakul","year":"2022","journal-title":"Int J Infect Dis"},{"key":"B7","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1097\/INF.0b013e3180cbd382","article-title":"Comparative safety profile of levofloxacin in 2523 children with a focus on four specific musculoskeletal disorders","volume":"26","author":"Noel","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1093\/cid\/cir531","article-title":"The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America","volume":"53","author":"Bradley","year":"2011","journal-title":"Clin Infect Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.1093\/cid\/cis370","article-title":"IDSA clinical practice guideline for acute bacterial rhinosinusitis in children and adults","volume":"54","author":"Chow","year":"2012","journal-title":"Clin Infect Dis"},{"key":"B10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/MPG.0000000000000375","article-title":"European Society for Pediatric Gastroenterology, Hepatology, and Nutrition\/European Society for Pediatric Infectious Diseases evidence-based guidelines for the management of acute gastroenteritis in children in Europe: update 2014","volume":"59","author":"Guarino","year":"2014","journal-title":"J Pediatr Gastr Nutr"},{"key":"B11","first-page":"10","article-title":"Expert consensus on the use of fluoroquinolones in children","volume":"28","author":"Wu","year":"2018","journal-title":"Pharmacy Today"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections","volume":"74","author":"Tamma","year":"2023","journal-title":"Clin Infect Dis"},{"key":"B13","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1354\/vp.41-6-673","article-title":"Early pathophysiologic feature of arthropathy in juvenile dogs induced by ofloxacin, a quinolone antimicrobial agent","volume":"41","author":"Yabe","year":"2004","journal-title":"Vet Pathol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1097\/00006454-199701000-00036","article-title":"Ciprofloxacin in pediatrics: worldwide clinical experience based on compassionate use\u2014safety report","volume":"16","author":"Hampel","year":"1997","journal-title":"Pediatr Infect Dis J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1179\/1973947815Y.0000000054","article-title":"Fluoroquinolones in children: update of the literature","volume":"27","author":"Bacci","year":"2015","journal-title":"J Chemother"},{"key":"B16","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1016\/S0140-6736(22)00087-3","article-title":"The overlooked pandemic of antimicrobial resistance","volume":"399","author":"Laxminarayan","year":"2022","journal-title":"Lancet"},{"key":"B17","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e00788","DOI":"10.1128\/aac.00788-19","article-title":"Clinical and microbiologic outcomes in patients with monomicrobial Stenotrophomonas maltophilia infections","volume":"63","author":"Ny","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"B19","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"B20","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2165\/00002018-200831010-00003","article-title":"Methods for causality assessment of adverse drug reactions: a systematic review","volume":"31","author":"Agbabiaka","year":"2008","journal-title":"Drug Saf"},{"key":"B21","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jclinepi.2005.08.012","article-title":"A new method for assessing drug causation provided agreement with experts\u2019 judgment","volume":"59","author":"Arimone","year":"2006","journal-title":"J Clin Epidemiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1097\/PTS.0000000000001213","article-title":"Comparison of WHO-UMC and Naranjo scales for causality assessment of reported adverse drug reactions","author":"Pandit","year":"2024","journal-title":"J Patient Saf"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1097\/01.inf.0000101994.25947.12","article-title":"Safety profile of quinolone antibiotics in the pediatric population","volume":"22","author":"Grady","year":"2003","journal-title":"Pediatr Infect Dis J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e29525","DOI":"10.1002\/pbc.29525","article-title":"Levofloxacin prophylaxis for pediatric leukemia patients: longitudinal follow-up for impact on health care-associated infections","volume":"69","author":"Davis","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"6550","DOI":"10.1002\/cam4.3249","article-title":"Fluoroquinolone prophylaxis does not increase risk of neuropathy in children with acute lymphoblastic leukemia","volume":"9","author":"Karol","year":"2020","journal-title":"Cancer Med"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1093\/cid\/cix644","article-title":"Levofloxacin prophylaxis during induction therapy for pediatric acute lymphoblastic leukemia","volume":"65","author":"Wolf","year":"2017","journal-title":"Clin Infect Dis"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e146","DOI":"10.1542\/peds.2013-3636","article-title":"Assessment of musculoskeletal toxicity 5 years after therapy with levofloxacin","volume":"134","author":"Bradley","year":"2014","journal-title":"Pediatrics"}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1381742\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,5]],"date-time":"2024-04-05T04:39:38Z","timestamp":1712291978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2024.1381742\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,5]]},"references-count":27,"alternative-id":["10.3389\/fped.2024.1381742"],"URL":"https:\/\/doi.org\/10.3389\/fped.2024.1381742","relation":{},"ISSN":["2296-2360"],"issn-type":[{"value":"2296-2360","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,5]]},"article-number":"1381742"}}